Zhou Peng, Zhao Xiao-Ni, Ma Yao-Yao, Tang Tong-Juan, Wang Shu-Shu, Wang Liang, Huang Jin-Ling
Department of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, People's Republic of China.
Institute of Integrated Chinese and Western Medicine, Anhui Academy of Chinese Medicine, Hefei, People's Republic of China.
J Food Biochem. 2022 Dec;46(12):e14376. doi: 10.1111/jfbc.14376. Epub 2022 Aug 9.
Coronary heart disease (CHD) is defined by atherosclerosis, which can result in stenosis or blockage of the arterial cavity, leading to ischemic cardiac diseases such as angina and myocardial infarction. Accumulating evidence indicates that the gut microbiota plays a vital role in the beginning and progression of CHD. The gut microbial metabolite, trimethylamine-N-oxide (TMAO), is intimately linked to the pathophysiology of CHD. TMAO is formed when trimethylamine (TMA) is converted by flavin-containing monooxygenases in the hepatocytes. Therefore, inhibition of TMA production is essential to reduce TMAO levels. Flavonoids may reduce the risk of death from cardiovascular disease. In this article, we reviewed and evaluated twenty-two flavonoids for the therapy of CHD based on their inhibition of TMA-lyase by molecular docking. Docking results revealed that baicalein, fisetin, acacetin, and myricetin in flavonoid aglycones, and baicalin, naringin, and hesperidin in flavonoid glycosides had a good binding effect with TMA-lyase. This indicates that these chemicals were the most active and could be used as lead compounds for structural modification in the future. PRACTICAL APPLICATIONS: Flavonoids are a large class of polyphenolic compounds found in fruits, vegetables, flowers, tea, and herbal medicines, which are inexorably metabolized and transformed into bioactive metabolites by α-rhamnosidase, β-glucuronidase, β-glucosidase, and nitroreductase produced by the gut microbiota, which plays a beneficial role in the prevention and treatment of cardiovascular diseases. Because flavonoids protect the cardiovascular system and regulate the gut microbiota, and the gut microbiota is directly connected to TMAO, thus, reducing TMAO levels involves blocking the transition of TMA to TMAO, which may be performed by reducing TMA synthesis. Molecular docking results found that baicalein, fisetin, acacetin, and myricetin in flavonoid aglycones, and baicalin, naringin, and hesperidin in flavonoid glycosides had good binding effects on TMA-lyase, which were the most active and could be used as lead compounds for structural modification.
冠心病(CHD)由动脉粥样硬化定义,动脉粥样硬化可导致动脉腔狭窄或阻塞,引发诸如心绞痛和心肌梗死等缺血性心脏病。越来越多的证据表明,肠道微生物群在冠心病的发生和发展中起着至关重要的作用。肠道微生物代谢产物三甲胺-N-氧化物(TMAO)与冠心病的病理生理学密切相关。当三甲胺(TMA)在肝细胞中被含黄素单加氧酶转化时会形成TMAO。因此,抑制TMA的产生对于降低TMAO水平至关重要。黄酮类化合物可能会降低心血管疾病导致的死亡风险。在本文中,我们基于分子对接对二十二种黄酮类化合物抑制TMA裂解酶的能力进行了综述和评估,以用于冠心病的治疗。对接结果显示,黄酮苷元中的黄芩素、非瑟酮、刺槐素和杨梅素,以及黄酮苷中的黄芩苷、柚皮苷和橙皮苷与TMA裂解酶具有良好的结合效果。这表明这些化合物活性最强,未来可作为结构修饰的先导化合物。实际应用:黄酮类化合物是一类在水果、蔬菜、花卉、茶和草药中发现的多酚类化合物,它们会被肠道微生物群产生的α-鼠李糖苷酶、β-葡萄糖醛酸酶、β-葡萄糖苷酶和硝基还原酶无情地代谢并转化为生物活性代谢产物,这在心血管疾病的预防和治疗中发挥着有益作用。因为黄酮类化合物可保护心血管系统并调节肠道微生物群,而肠道微生物群与TMAO直接相关,因此,降低TMAO水平涉及阻断TMA向TMAO的转变,这可通过减少TMA合成来实现。分子对接结果发现,黄酮苷元中的黄芩素、非瑟酮、刺槐素和杨梅素,以及黄酮苷中的黄芩苷、柚皮苷和橙皮苷对TMA裂解酶具有良好的结合效果,它们活性最强,可作为结构修饰的先导化合物。